Maternal Family History of Diabetes Is Associated With a Reduced Risk of Cardiovascular Disease in Women With Type 2 Diabetes

The Fremantle Diabetes Study

OBJECTIVE — To investigate whether parental family history of diabetes influences cardiovascular outcomes in type 2 diabetes.

RESEARCH DESIGN AND METHODS — We studied 1,294 type 2 diabetic patients (mean age 64.1 years, 51.2% female) recruited to a community-based cohort study from 1993 to 1996 and followed until mid-2006. A data linkage system assessed all-cause and cardiac mortality, incident myocardial infarction, and stroke. Cox proportional hazards modeling was used to determine the influence of maternal or paternal family history on these outcomes.

RESULTS — A maternal family history of diabetes was reported by 20.4% of the cohort, 8.3% reported paternal family history, and 2.0% reported both parents affected. Maternal and paternal family history was associated with earlier age of diabetes onset, and maternal family history was associated with worse glycemic control. For all patients, maternal family history was significantly associated with reduced risk of all-cause mortality and cardiac mortality. When analyzed by sex, maternal family history had no effect on male patients, whereas female patients with diabetic mothers had significantly reduced hazard ratios for death from all causes (0.63 [95% CI 0.41–0.96]; P = 0.033), for death from cardiac causes (0.32 [0.14–0.72]; P = 0.006), and for first myocardial infarction (0.45 [0.26–0.76]; P = 0.003). Paternal family history status was not associated with these outcomes.

CONCLUSIONS — A maternal family history of diabetes confers relative protection against cardiovascular disease in female patients but not in male patients with type 2 diabetes. Paternal family history is associated with risks equivalent to those without a family history of diabetes. Some of the clinical heterogeneity of type 2 diabetes is related to maternal transmission effects with differential impact on male and female patients.

The complex etiology of type 2 diabetes involves both genetic components and environmental exposures. In type 2 diabetes, there is a well-documented association between a family history of the disease and its development (1,2). Maternal and paternal family histories of diabetes are both associated with an earlier age of onset (2–4), and this effect is more marked when multiple family members are affected (5). In addition, intrauterine exposure to diabetes increases the risk of diabetes in offspring (6), which may help explain the reported excess maternal transmission (7,8).

Patients with familial diabetes have relatively poor glycemic control, but few other clinical differences have been reported (4,5,9,10). An early age of onset and poor glycemic control would both be expected to have a negative impact on the development of chronic complications, but no such longitudinal data have been published. In the present study, we examined relationships among parental diabetes and important clinical outcomes in type 2 diabetes, including incident coronary heart disease (CHD) and all-cause and cardiac mortality in a large community-based sample of patients with type 2 diabetes. We hypothesized that familial diabetes would indicate worse clinical outcomes. We investigated potential relationships in male and female patients separately, given the known differences in CHD incidence between men and women with diabetes (11).

RESEARCH DESIGN AND METHODS — The present sample comprised all participants with type 2 diabetes enrolled in the Fremantle Diabetes Study (FDS), a longitudinal observational study conducted from a postcode-defined urban Australian community of 120,097 people. Descriptions of recruitment, sample characteristics including classification of diabetes type, and details of nonrecruited patients have been published previously (12,13). Of 2,258 diabetic patients identified between 1993 and 1996, 1,426 (63%) were recruited and 1,294 had type 2 diabetes. The study protocol was approved by the Fremantle Hospital Human Rights Committee, and all subjects gave informed consent before participation.

Clinical assessment
Each participant underwent a comprehensive assessment at FDS entry that
Familial diabetes and cardiovascular disease

comprised 1) a standard questionnaire including questions on diabetes symptoms at onset, self–glucose monitoring, attendance at diabetes education/dietitian sessions, lifestyle factors, education, self-assessed ethnicity, fluency with English, and knowledge of diabetes (12); 2) a detailed physical examination; and 3) the provision of fasting blood and urine samples for automated biochemical tests performed in a single laboratory. As part of 1) above, all participants were asked to provide details of relatives with known diabetes (including a specific enquiry as to the status of mother, father, grandparents, son, daughter, grandchildren, brother, sister, uncle, aunt, and other) and their respective diabetes treatment status (whether insulin or tablet/diet treated).

Complications were identified using standard definitions (13). Peripheral neuropathy was defined as a score >2 of 8 on the Michigan Neuropathy Screening Instrument clinical portion. Retinopathy was taken as any grade detected by direct/indirect ophthalmoscopy and/or ophthalmologist assessment. Nephropathy was defined as a first-morning urinary albumin-to-creatinine ratio ≥3.0 mg/mmol. Self-reported stroke/transient ischemic attack were amalgamated with prior hospitalizations to define baseline cerebrovascular disease status. Patients were classified as having CHD if there was a self-reported history of or hospitalization for myocardial infarction, angina, revascularization, or angioplasty. Peripheral arterial disease was considered to be present when the ankle-to-brachial index was ≤0.90 or by the presence of a diabetes-related amputation.

Incident cardiovascular disease and mortality

The Hospital Morbidity Data System records all public and private hospital separations in Western Australia and, together with the death register, forms part of the Western Australia Data Linkage System (WADLS) (14). The FDS database was linked with the WADLS to provide morbidity/mortality data from 1 January 1993 until the end of June 2006. Hospitalizations for CHD and cerebrovascular disease were extracted from WADLS to calculate prevalent and incident myocardial infarctions and strokes. The causes of death were reviewed independently by two of the authors (D.G.B. and T.M.E.D.) and classified as being due to cardiac causes or not under the system used in the UK Prospective Diabetes Study (15).

When there was disagreement between raters, a final consensus decision was reached.

Statistical methods

Pancreatic β-cell function and insulin sensitivity were estimated from fasting serum glucose (FSG) and serum insulin concentrations using homeostasis model assessment (16). All data were analyzed using SPSS for Windows (version 14.0.2). Because GHB, FSG, serum triglycerides, urinary albumin-to-creatinine ratio, insulin sensitivity, and pancreatic β-cell function were not normally distributed, they were log-transformed before analysis. Data are reported as means ± SD, geometric mean (SD range), medians (interquartile range), or percentages. ANOVA and Fisher’s exact tests were used to test equality of means for normally distributed continuous and categorical variables, respectively. Variables with a nonparametric distribution were analyzed using the Kruskal-Wallis test. If differences were detected, pairwise comparison with a Student t test, Fisher exact test, or Mann-Whitney test was undertaken. Multivariate linear regression analysis was used to investigate effects on glycemic and blood pressure control after appropriate adjustment. Cox proportional hazards modeling (with forward conditional, variable entry, and removal at P < 0.05 and > 0.10, respectively) was used to determine independent predictors of all-cause mortality, cardiac mortality, first-time incident myocardial infarction, and first incident stroke (subjects with prior events were excluded from relevant models). All clinically plausible variables were considered for entry into the models before family history status was entered.

RESULTS

Baseline sample characteristics

The patient sample was aged 64.1 ± 11.3 years and 51.2% were women. A parental family history of diabetes was reported by 397 patients (30.7%), of whom 264 (20.4%) had a maternal family history, 107 (8.3%) had a paternal family history, and 26 (2.0%) had both parents affected (Table 1). Diabetes onset occurred at a significantly younger age in patients with parental diabetes. At the time of baseline assessment, they were also younger but had duration of diabetes similar to that of patients without a family history. Patients with a maternal family history had significantly higher FSG and GHB levels. Systolic blood pressure was lower with both maternal and paternal family histories.

After adjustment for age, diabetes duration, and treatment type, both FSG and GHB remained significantly higher with maternal family history [β ln(FSG) 0.05 (95% CI 0.01–0.09) mmol/l; P = 0.017 and ln(GHB) 0.03% (0.02–0.07); P = 0.001], but not with a paternal family history (P = 0.39). After adjustment for age, no significant difference in systolic blood pressure levels was seen with maternal or paternal family histories. There were no differences by family history in proportions with GAD antibody positivity, pancreatic β-cell function, or insulin sensitivity, exercise levels, alcohol intake, or proportions taking blood pressure–lowering or lipid-lowering medications (data not shown).

Family history, mortality, myocardial infarction, and stroke

By the end of June 2006, crude all-cause mortality rates were significantly lower in patients with maternal and paternal family histories (Table 1). In Cox regression models (Table 2), we examined the effect of family history unadjusted (model 1), after adjustment for age and sex (where appropriate, model 2), and after adjustment for identified relevant variables (model 3, variables listed in supplementary Table 1, available in an online appendix at http://care.diabetesjournals.org/cgi/content/full/dc10-0147/DC1). In adjusted models, maternal or paternal family history was entered into the most parsimonious model to assess whether either was an independent determinant of outcome. For all patients, maternal family history was associated with a significantly reduced risk of death from all causes and from cardiac causes, whereas there was a trend toward a reduction in the risk of incident myocardial infarction (Table 2). When analyzed by sex, the protective effect of maternal family history on all-cause and cardiac mortality was only significant in female patients and was significant for incident myocardial infarction in women. Paternal family history was not associated with differences in clinical outcomes.

Maternal family history, diabetes presentation, and health-related behaviors

To explore possible reasons for a protective effect of a maternal family history, we assessed relationships with diabetes pre-
sentation, self-care behaviors, and knowledge of diabetes. No statistical differences were found in mode of presentation at diagnosis (symptomatic or incidental), the nature of the presenting symptoms (thirst, polyuria, fatigue, weight loss, or visual blurring), the frequency of medical visits (family doctors, diabetes clinics, diabetes specialists, diabetes educators, and other medical specialists), or in the performance of self-monitoring of blood glucose. Female patients with either parent having diabetes had higher diabetes knowledge scores than patients without a family history \(P = 0.033\), but this was not seen in men with a parental family history.

CONCLUSIONS — The results of our longitudinal observational study are consistent with those of previous reports in showing that patients with a parental family history of diabetes develop diabetes ~5 years before their counterparts without a family history \(2–5\). We also found that our patients with a maternal family history had worse glycemic control. Despite these unfavorable features, female patients with a maternal family history had a lower risk of myocardial infarction and reduced all-cause and cardiac mortality. Because women with type 2 diabetes have a substantially increased risk of cardiovascular disease compared with nondiabetic women \(11\), these data suggest that diabetic women with a maternal family history have a risk of myocardial infarction and death that is intermediate between diabetic women without a family history and nondiabetic women. Male patients with a maternal family history and patients of either sex with a paternal family history had outcomes comparable to those in patients without a family history.

In explaining these findings, consideration needs to be given to the relative impact of maternal versus paternal family history on cardiovascular disease in diabetes and why a benefit should be confined to females. Familial disease can be transmitted by genetic and nongenetic in-
Familial diabetes and cardiovascular disease

Table 2—Hazard ratios for clinical outcomes in patients with type 2 diabetes by parental history

|                      | No family history | Family history | Log-rank P value | Hazard ratios (95% CI) |
|----------------------|-------------------|----------------|-----------------|-----------------------|
|                      | No. patients | No. events | Absolute risk* | No. patients | No. events | Absolute risk* |                      |
| All patients: maternal history |              |            |                |              |            |                |                      |
| All-cause mortality   |              |            |                |              |            |                |                      |
| Model 1†             | 1,001        | 410        | 43.1           | 290          | 81         | 26.4           | <0.001               |
| Model 2‡             |              |            |                |              |            |                | 0.60 (0.48–0.77)     |
| Model 3§             |              |            |                |              |            |                | 0.81 (0.64–1.03)     |
|                      |              |            |                |              |            |                | 0.69 (0.52–0.92)     |
| Cardiac mortality    |              |            |                |              |            |                |                      |
| Model 1†             | 1,001        | 172        | 18.1           | 290          | 25         | 8.2            | <0.001               |
| Model 2‡             |              |            |                |              |            |                | 0.45 (0.30–0.69)     |
| Model 3§             |              |            |                |              |            |                | 0.61 (0.40–0.93)     |
|                      |              |            |                |              |            |                | 0.50 (0.31–0.82)     |
| Myocardial infarction|              |            |                |              |            |                |                      |
| Model 1†             | 977          | 227        | 25.6           | 281          | 51         | 17.9           | 0.023                |
| Model 2‡             |              |            |                |              |            |                | 0.70 (0.52–0.95)     |
| Model 3§             |              |            |                |              |            |                | 0.91 (0.67–1.24)     |
|                      |              |            |                |              |            |                | 0.73 (0.52–1.03)     |
| Stroke               |              |            |                |              |            |                |                      |
| Model 1†             | 998          | 106        | 11.5           | 290          | 26         | 8.6            | 0.19                 |
| Model 2‡             |              |            |                |              |            |                | 0.75 (0.49–1.15)     |
| Model 3§             |              |            |                |              |            |                | 1.00 (0.65–1.54)     |
|                      |              |            |                |              |            |                | 0.73 (0.45–1.20)     |
| All patients: paternal history |              |            |                |              |            |                |                      |
| All-cause mortality   |              |            |                |              |            |                |                      |
| Model 1†             | 1,159        | 452        | 40.3           | 132          | 39         | 28.8           | 0.039                |
| Model 2‡             |              |            |                |              |            |                | 0.71 (0.51–0.98)     |
| Model 3§             |              |            |                |              |            |                | 0.92 (0.66–1.28)     |
|                      |              |            |                |              |            |                | 1.06 (0.73–1.54)     |
| Cardiac mortality    |              |            |                |              |            |                |                      |
| Model 1†             | 1,159        | 184        | 16.4           | 132          | 13         | 9.6            | 0.06                 |
| Model 2‡             |              |            |                |              |            |                | 0.59 (0.33–1.03)     |
| Model 3§             |              |            |                |              |            |                | 0.76 (0.43–1.34)     |
|                      |              |            |                |              |            |                | 0.96 (0.52–1.78)     |
| Myocardial infarction|              |            |                |              |            |                |                      |
| Model 1†             | 1,128        | 258        | 24.7           | 130          | 20         | 15.6           | 0.049                |
| Model 2‡             |              |            |                |              |            |                | 0.64 (0.40–1.00)     |
| Model 3§             |              |            |                |              |            |                | 0.79 (0.50–1.25)     |
|                      |              |            |                |              |            |                | 0.98 (0.60–1.61)     |
| Stroke               |              |            |                |              |            |                |                      |
| Model 1†             | 1,156        | 120        | 11.0           | 132          | 12         | 9.0            | 0.50                 |
| Model 2‡             |              |            |                |              |            |                | 0.81 (0.45–1.47)     |
| Model 3§             |              |            |                |              |            |                | 1.10 (0.61–2.00)     |
|                      |              |            |                |              |            |                | 1.15 (0.60–2.21)     |
| Women: maternal history |              |            |                |              |            |                |                      |
| All-cause mortality   |              |            |                |              |            |                |                      |
| Model 1†             | 495          | 179        | 36.9           | 166          | 41         | 22.8           | 0.004                |
| Model 2‡             |              |            |                |              |            |                | 0.61 (0.44–0.86)     |
| Model 3§             |              |            |                |              |            |                | 0.81 (0.58–1.14)     |
|                      |              |            |                |              |            |                | 0.63 (0.41–0.96)     |
| Cardiac mortality    |              |            |                |              |            |                |                      |
| Model 1†             | 495          | 77         | 15.9           | 166          | 10         | 5.6            | 0.001                |
| Model 2‡             |              |            |                |              |            |                | 0.35 (0.18–0.68)     |
| Model 3§             |              |            |                |              |            |                | 0.47 (0.24–0.91)     |
|                      |              |            |                |              |            |                | 0.32 (0.14–0.72)     |
| Myocardial infarction|              |            |                |              |            |                |                      |
| Model 1†             | 485          | 104        | 22.6           | 161          | 23         | 13.7           | 0.029                |
| Model 2‡             |              |            |                |              |            |                | 0.61 (0.39–0.96)     |
| Model 3§             |              |            |                |              |            |                | 0.83 (0.53–1.31)     |
|                      |              |            |                |              |            |                | 0.45 (0.26–0.76)     |
| Stroke               |              |            |                |              |            |                |                      |
| Model 1†             | 495          | 52         | 11.0           | 166          | 14         | 7.9            | 0.27                 |
| Model 2‡             |              |            |                |              |            |                | 0.72 (0.40–1.30)     |
| Model 3§             |              |            |                |              |            |                | 0.93 (0.51–1.67)     |
|                      |              |            |                |              |            |                | 0.73 (0.40–1.36)     |

(continued)
Table 2—Continued

|                         |                      |                      |                      |                      | Log-rank | Hazard ratios |
|-------------------------|----------------------|----------------------|----------------------|----------------------|---------|---------------|
|                         | No. patients | No. events | Absolute risk* | No. patients | No. events | Absolute risk* | P value | (95% CI)       |
| Women: paternal history |                      |                      |                      |                      |         |               |
| All-cause mortality     | Model 1†       | 597            | 206            | 34.5           | 64        | 14            | 20.4     | 0.047          | 0.58 (0.34–1.00) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |
| Cardiac mortality       | Model 1†       | 597            | 83             | 13.9           | 64        | 4             | 5.8      | 0.08           | 0.42 (0.15–1.14) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |
| Myocardial infarction   | Model 1†       | 583            | 121            | 21.6           | 63        | 6             | 9.0      | 0.032          | 0.42 (0.19–0.95) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |
| Stroke                  | Model 1†       | 597            | 64             | 11.0           | 64        | 2             | 2.9      | 0.045          | 0.26 (0.06–1.07) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |
| Men: maternal history   | Model 1†       | 506            | 231            | 49.6           | 124       | 40            | 31.5     | 0.006          | 0.63 (0.45–0.88) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |
| Cardiac mortality       | Model 1†       | 506            | 95             | 20.4           | 124       | 15            | 11.8     | 0.044          | 0.58 (0.33–0.99) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |
| Myocardial infarction   | Model 1†       | 492            | 123            | 28.8           | 120       | 28            | 23.9     | 0.40           | 0.84 (0.56–1.26) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |
| Stroke                  | Model 1†       | 503            | 54             | 12.0           | 124       | 12            | 9.6      | 0.48           | 0.80 (0.43–1.49) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |
| Men: paternal history   | Model 1†       | 562            | 246            | 46.7           | 68        | 25            | 37.5     | 0.30           | 0.80 (0.53–1.21) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |
| Cardiac mortality       | Model 1†       | 562            | 101            | 19.2           | 68        | 9             | 13.5     | 0.31           | 0.71 (0.36–1.39) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |
| Myocardial infarction   | Model 1†       | 545            | 137            | 28.4           | 67        | 14            | 22.9     | 0.45           | 0.81 (0.47–1.40) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |
| Stroke                  | Model 1†       | 559            | 56             | 11.0           | 68        | 10            | 15.4     | 0.33           | 1.40 (0.71–2.74) |
|                         | Model 2‡       |                      |                      |                      |         |               |
|                         | Model 3§       |                      |                      |                      |         |               |

*Events per 1,000 person-years. †Model 1 is unadjusted. ‡Model 2 includes age and sex (where applicable). §Model 3 includes all variables in the respective most parsimonious models (supplementary Table 1).
Familial diabetes and cardiovascular disease

...and that seen in nonfamilial type 2 diabetes. One possible explanation is that... factors persist, whereas fetal nonglycemic cardiovascular risk factors wane with age.

There are several potential explanations as to why maternal family history had a differential effect in male and female patients. There are increasing reports of sex differences resulting from genetic and epigenetic transmission in a range of common complex disorders, including cardiovascular disease and type 2 diabetes (8,22). For example, sex differences were reported in an animal model of fetal imprinting in which male offspring developed hypertension, but females were protected (23). It is also possible that men give less accurate family histories, although studies on the analytical validity of family history reports do not indicate a sex bias (24).

The study strengths include the large and representative nature of the sample, the detailed nature of clinical and demographic assessment, and the completeness of ascertainment of the major clinical end points using a well-validated data linkage system. The major limitation relates to the method used to assess family history. Patients classified as having no family history of diabetes included those with limited or no knowledge of the health status of their relatives. This may have led to instances of a false-negative family history and thus an overestimation of the maternal transmission of diabetes because an unknown paternal status is more common in this situation (25).

Other potential limitations include recall bias for family history, demonstrated to be minimal in diabetes (24), and a lack of statistical power to detect effects from paternal family history as the number of affected patients was relatively small. We were unable to distinguish gestational diabetes mellitus or the time of onset in the parents with diabetes and the study did not take account of other relevant family history such as having affected siblings.

In summary, the present study demonstrates that women with type 2 diabetes and a maternal family history of diabetes have a lower risk of myocardial infarction and death from cardiac causes than women without a family history of diabetes. These data indicate another source of heterogeneity in the clinical impact of type 2 diabetes and have relevance for understanding the pathophysiology, epidemiology, and public health impact of cardiovascular disease in women with type 2 diabetes.

Acknowledgments — The Fremantle Diabetes Study was funded by a Raine grant from the University of Western Australia. T.M.E.D. was supported by a National Health and Medical Research Foundation Practitioner Fellowship.

No potential conflicts of interest relevant to this article were reported.

References
1. Harrison TA, Hindorff LA, Kim H, Wines RC, Bowen DJ, McGrath BB, Edwards KL. Family history of diabetes as a potential public health tool. Am J Prev Med 2003; 24:152–159
2. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes 2000;49:2201–2207
3. Mitchell BD, Kammerer CM, Reinhart LJ, Stern MP. NIDDM in Mexican-American families: heterogeneity by age of onset. Diabetes Care 1994;17:567–573
4. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Influence of a familial history of diabetes on the clinical characteristics of patients with type 2 diabetes mellitus. Diabet Med 2000;17:538–542
5. Molonyea L, Constantino M, Yue D. Strong family history predicts a younger age of onset for subjects diagnosed with type 2 diabetes. Diabetes Obes Metab 2004;6:187–194
6. Dabelea D, Hanson RL, Lindsay RS, Pettitt DJ, Imperatore G, Gabir MM, Roumani J, Bennett PH, Knowler WC. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes 2000;49:2208–2211
7. Alcolado JC, Laji K, Gill-Randall R. Maternal transmission of diabetes. Diabet Med 2002;19:89–98
8. Fettia LS, Sobngwi E, Serradas P, Calvo F, Gautier JF. Consequences of fetal exposure to maternal diabetes in offspring (Review). J Clin Endocrinol Metab 2006;91:3718–3724
9. Gong L, Kao WH, Brancati FL, Battist Turner M, Gary TL. Association between parental history of type 2 diabetes and glycemic control in urban African Americans. Diabetes Care 2008;31:1773–1776
10. Gilliam LR, Liese AD, Bloch CA, Davis C, Snively BM, Curb D, Williams DE, Pforker C. Family history of diabetes, autoimmunity, and risk factors for cardiovascular disease among children with diabetes in the SEARCH for Diabetes in Youth Study. Pediatr Diabetes 2007;8:354–361
11. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007;167:1145–1151
12. Bruce DG, Davis WA, Cull CA, Davis TM. Diabetes education and knowledge in patients with type 2 diabetes from the community: the Fremantle Diabetes Study. J Diabetes Complications 2003;17:82–89

13. Norman PE, Davis WA, Bruce DG, Davis TM. Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2006;29:575–580

14. Holman CDJ, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999;23:453–459

15. Turner RC, Mills H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman HH. Risk factors for coronary artery disease in non-insulin dependent diabetes: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J 1998;316:823–828

16. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191–2192

17. Tseng CH. Effect of parental hypertension and/or parental diabetes on hypertension in Taiwanese diabetic patients. Eur J Clin Invest 2007;37:870–877

18. Sánchez CD, Newby LK, McGuire DK, Hasselblad V, Feinglos MN, Ohman EM. Diabetes-related knowledge, atherosclerotic risk factor control, and outcomes in acute coronary syndromes. Am J Cardiol 2005;95:1290–1294

19. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25:1862–1868

20. Carr DB, Utschneider KM, Hull RL, Tong J, Wallace TM, Kodama K, Shofer JB, Heckbert SR, Boyko EJ, Fujimoto WY, Kahn SE. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. Diabetes Care 2006;29:2078–2083

21. Choo KE, Lau KB, Davis WA, Chew PH, Jenkins AJ, Davis TM. Cardiovascular risk factors in pre-pubertal Malays: effects of diabetic parentage. Diabetes Res Clin Pract 2007;76:119–125

22. Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H, Absher D, Li J, Fair JM, Rubin GD, Sidney S, Fortmann SP, Go AS, Hlatky MA, Myers RM, Risch N, Quertermous T. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet 2008;17:2320–2328

23. Ojeda NB, Grigore D, Robertson EB, Alexander BT. Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring. Hypertension 2007;50:679–685

24. Kahn LB, Marshall JA, Baxter J, Shetterly SM, Hamman RF. Accuracy of reported family history of diabetes mellitus: results from San Luis Valley Diabetes Study. Diabetes Care 1990;13:796–798

25. Thorand B, Liese AD, Metzger MH, Reitmeir P, Schneider A, Löwel H. Can inaccuracy of reported parental history of diabetes explain the maternal transmission hypothesis for diabetes? Int J Epidemiol 2001;30:1084–1089